Susquehanna International Group
XERS icon

Susquehanna International Group’s Xeris Biopharma Holdings XERS Stock Holding History

Susquehanna International Group’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.66M Buy
286,071
+168,716
+144% +$1.12M ﹤0.01% 6604
2025
Q4 		$921K Buy
117,355
+35,884
+44% +$282K ﹤0.01% 7374
2025
Q3 		$663K Sell
81,471
-324,731
-80% -$2.16M ﹤0.01% 8335
2025
Q2 		$1.9M Sell
406,202
-231,580
-36% -$1.06M ﹤0.01% 5904
2025
Q1 		$3.5M Buy
637,782
+530,438
+494% +$2.14M ﹤0.01% 4347
2024
Q4 		$364K Buy
107,344
+27,429
+34% +$88.2K ﹤0.01% 9397
2024
Q3 		$228K Buy
79,915
+47,669
+148% +$122K ﹤0.01% 10189
2024
Q2 		$72.6K Buy
32,246
+4,856
+18% +$9.79K ﹤0.01% 11227
2024
Q1 		$60.5K Sell
27,390
-135,839
-83% -$351K ﹤0.01% 11475
2023
Q4 		$384K Buy
163,229
+56,998
+54% +$105K ﹤0.01% 9287
2023
Q3 		$198K Sell
106,231
-17,441
-14% -$40K ﹤0.01% 10243
2023
Q2 		$324K Sell
123,672
-9,721
-7% -$24.7K ﹤0.01% 9278
2023
Q1 		$217K Buy
133,393
+69,824
+110% +$87.4K ﹤0.01% 10421
2022
Q4 		$84.5K Sell
63,569
-32,218
-34% -$45.5K ﹤0.01% 11090
2022
Q3 		$149K Buy
95,787
+32,395
+51% +$53.6K ﹤0.01% 11246
2022
Q2 		$98K Sell
63,392
-359,784
-85% -$759K ﹤0.01% 11501
2022
Q1 		$1.08M Sell
423,176
-411,360
-49% -$1M ﹤0.01% 6912
2021
Q4 		$2.44M Buy
834,536
+225,009
+37% +$486K ﹤0.01% 5045
2021
Q3 		$1.49M Buy
609,527
+528,795
+655% +$1.54M ﹤0.01% 6499
2021
Q2 		$329K Buy
+80,732
New +$308K ﹤0.01% 10568
2021
Q1 		– Sell
-145,255
Closed -$783K – 12927
2020
Q4 		$715K Buy
+145,255
New +$727K ﹤0.01% 7493
2020
Q3 		– Sell
-12,392
Closed -$49.5K – 11236
2020
Q2 		$33K Sell
12,392
-4,126
-25% -$14.4K ﹤0.01% 9851
2020
Q1 		$32K Buy
+16,518
New +$71K ﹤0.01% 9815
2019
Q4 		– Sell
-20,039
Closed -$197K – 10783
2019
Q3 		$197K Buy
20,039
+9,700
+94% +$109K ﹤0.01% 9107
2019
Q2 		$118K Buy
+10,339
New +$109K ﹤0.01% 9526

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group's XERS Position: Q1 2026 in Review

Susquehanna International Group increased its Xeris Biopharma Holdings (XERS) stake by 144% in Q1 2026, buying an estimated $1.12M and bringing the position to 286,071 shares worth $1.66M. The position accounts for ﹤0.01% of the portfolio, ranked #6604.

Susquehanna International Group first reported a position in XERS in Q2 2019 and has held it in 25 quarters since. The position peaked at $3.5M in Q1 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

  • Susquehanna International Group held 286,071 shares of Xeris Biopharma Holdings worth $1.66M as of Q1 2026.
  • Susquehanna International Group bought 168,716 Xeris Biopharma Holdings shares in Q1 2026, an estimated $1.12M.
  • Xeris Biopharma Holdings made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #6604 holding.
  • Susquehanna International Group first reported a position in Xeris Biopharma Holdings in Q2 2019 and has held it in 25 quarters since.
  • Susquehanna International Group's Xeris Biopharma Holdings position peaked at $3.5M in Q1 2025.
  • 237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.